PRAXIS PRECISION MEDICINES, INC. (PRAX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -378.17M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 290.71M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-378.17M | (m) | (m) | $290.71M | (m) | (m) |
| 2026-03-31 | $-357.33M | (m) | (m) | $284.30M | (m) | (m) |
| 2025-12-31 | $-326.20M | $0.00 | (m) | $267.12M | (m) | (m) |
| 2025-09-30 | $-293.11M | $7.46M | (m) | $245.90M | (m) | -3927.51% |
| 2025-06-30 | $-271.59M | $7.76M | (m) | $221.98M | (m) | -3497.57% |
| 2025-03-31 | $-233.01M | $8.12M | (m) | $186.24M | (m) | -2868.84% |
| 2024-12-31 | $-200.16M | $8.55M | (m) | $152.41M | (m) | -2340.29% |
| 2024-09-30 | $-164.01M | $1.60M | (m) | $114.51M | (m) | -10219.00% |
| 2024-06-30 | $-132.70M | $1.77M | (m) | $89.89M | (m) | -7492.72% |
| 2024-03-31 | $-130.17M | $2.19M | (m) | $88.25M | (m) | -5930.21% |
| 2023-12-31 | $-126.37M | $2.45M | (m) | $86.77M | (m) | -5164.41% |
| 2023-09-30 | $-140.02M | (m) | (m) | $96.71M | (m) | (m) |
| 2023-06-30 | $-158.79M | (m) | (m) | $109.89M | (m) | (m) |
| 2023-03-31 | $-184.23M | (m) | (m) | $127.89M | (m) | (m) |
| 2022-12-31 | $-214.99M | (m) | (m) | $155.04M | (m) | (m) |
| 2022-09-30 | $-232.19M | (m) | (m) | $170.22M | (m) | (m) |
| 2022-06-30 | $-232.67M | (m) | (m) | $172.92M | (m) | (m) |
| 2022-03-31 | $-208.76M | (m) | (m) | $154.98M | (m) | (m) |
| 2021-12-31 | $-167.33M | (m) | (m) | $120.26M | (m) | (m) |
| 2021-09-30 | $-134.39M | (m) | (m) | $93.02M | (m) | (m) |
| 2021-06-30 | $-105.83M | (m) | (m) | $72.67M | (m) | (m) |
| 2021-03-31 | $-80.92M | (m) | (m) | $56.04M | (m) | (m) |
| 2020-12-31 | $-61.97M | (m) | (m) | $44.98M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-35.79M | (m) | (m) | $29.56M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |